Equities research analysts expect Hill-Rom Holdings, Inc. (NYSE:HRC) to report earnings of $1.13 per share for the current quarter, Zacks reports. Four analysts have provided estimates for Hill-Rom’s earnings, with the highest EPS estimate coming in at $1.14 and the lowest estimate coming in at $1.13. Hill-Rom posted earnings per share of $0.91 during the same quarter last year, which would suggest a positive year-over-year growth rate of 24.2%. The company is scheduled to issue its next quarterly earnings report on Friday, July 27th.
According to Zacks, analysts expect that Hill-Rom will report full year earnings of $4.62 per share for the current financial year, with EPS estimates ranging from $4.60 to $4.63. For the next year, analysts anticipate that the firm will report earnings of $5.11 per share, with EPS estimates ranging from $5.06 to $5.17. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Hill-Rom.
Get Hill-Rom alerts:
Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, April 27th. The medical technology company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.03. The business had revenue of $710.50 million for the quarter, compared to analyst estimates of $707.54 million. Hill-Rom had a return on equity of 20.18% and a net margin of 6.85%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the company posted $0.88 EPS.
HRC has been the topic of several research reports. Zacks Investment Research lowered Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Goldman Sachs initiated coverage on Hill-Rom in a research report on Wednesday, April 4th. They issued a “neutral” rating and a $85.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hill-Rom in a research report on Friday, January 26th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Hill-Rom presently has a consensus rating of “Buy” and an average target price of $94.00.
In other Hill-Rom news, SVP Deborah Rasin sold 7,590 shares of the firm’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $86.02, for a total value of $652,891.80. Following the transaction, the senior vice president now directly owns 14,028 shares of the company’s stock, valued at $1,206,688.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.90% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in shares of Hill-Rom by 3.3% during the first quarter. Principal Financial Group Inc. now owns 290,643 shares of the medical technology company’s stock worth $25,286,000 after acquiring an additional 9,328 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Hill-Rom during the first quarter worth about $1,601,000. Wesbanco Bank Inc. purchased a new stake in shares of Hill-Rom during the first quarter worth about $2,977,000. Xact Kapitalforvaltning AB increased its position in shares of Hill-Rom by 32.8% during the first quarter. Xact Kapitalforvaltning AB now owns 8,102 shares of the medical technology company’s stock worth $705,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of Hill-Rom by 23.4% during the first quarter. Legal & General Group Plc now owns 86,217 shares of the medical technology company’s stock worth $7,500,000 after acquiring an additional 16,358 shares during the last quarter. 81.38% of the stock is currently owned by institutional investors and hedge funds.
Hill-Rom traded up $0.15, hitting $90.72, during mid-day trading on Monday, MarketBeat.com reports. The company had a trading volume of 306,900 shares, compared to its average volume of 491,642. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.85 and a quick ratio of 1.36. Hill-Rom has a 1 year low of $71.91 and a 1 year high of $91.32. The firm has a market capitalization of $6.00 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 1.38 and a beta of 0.98.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 22nd will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.88%. The ex-dividend date is Thursday, June 21st. Hill-Rom’s dividend payout ratio (DPR) is presently 20.73%.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Get a free copy of the Zacks research report on Hill-Rom (HRC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com